Dear shareholders,In 2023, the global economy showed signs of recovery, yetstillfilled with challenges. The entire team of Fosun worked together, actively seized opportunities and insisted on pursuing sustainable growth, resulting in the overall achievement of steady growth.As a global innovation-driven consumer group, the Group always adheres to the strategy

Results Highlights• Business Volume1reached RMB18,125.1 million, with a year-on-year growth of 19%, surpassing the 28% recorded in 2019, while revenue increased by 24% year-on-year to RMB17,151.8 million•Profit attributable to equity holders turned around to RMB307.2 million• Club Med achieved a Business Volume of RMB15,122.5 million, representing a 19% year-on-

Recently, an Innovation Passport designation has been awarded to serplulimab, Henlius’self-developed anti-PD-1 mAb (trade name in China: HANSIZHUANG), for the treatment of extensive stage small cell lung cancer (ES-SCLC) by the U.K. Innovative Licensing and Access Pathway Steering Group including the Medicines & Healthcare products Regulatory Agency (MHRA). This design

Shanghai, China, Mar 12th, 2024 - Shanghai Henlius Biotech, Inc. (2696.HK) announced the investigational new drug (IND) application for clinical trial of HLX6018，a novel anti-GARP/TGF-β1 monoclonal antibody (mAb) independently developed by the company, was approved by the National Medical Products Administration (NMPA) for the treatment of idiopathic pulmonary fibrosis

On 12 March, Fosun Pharma announced that its controlled subsidiaries/companies, Fuxin Shenyao, Fosun Pharma (Shenzhen) and Shanghai Rehabilitation Equity Investment Fund Management Co., Ltd., together with seven investors including Shenzhen FoF, plan to jointly establish a target fund. The proposed fund-raising size of the target fund is RMB5.0 billion,

Spring Appreciation in Yuyuan GardenRecently, the 2024 Yuyuan Garden Spring Appreciation event, hosted by the Foreign Affairs Office of Shanghai Municipal People's Government and the Huangpu District Government, and organized by Shanghai Yuyuan Tourist Mart (Group) Co., Ltd., was successfully held. The event invited consular officials from nearly 40 co

Recently, Henlius' self-developed and manufactured HANQUYOU (trastuzumab, trade names: Zercepac^®in Europe, Tuzucip^®and Trastucip^®in Australia) has been approved for marketing in Thailand and the Philippines under the trade names of TRAZHER^®and Hertumab^®, respectively, for the treatment of HER2-positive breast cancer and gastric cancer. Up to no

Shanghai, China, March 4th, 2024 – Henlius (2696.HK) released a positive profit forecast. Based on the preliminary assessment of the unaudited consolidated management accounts for the year ended 31 December, 2023 (the “Reporting Period”) and the information currently available to the Board,itis expected that the company will record a profit for the year of no l

On 24 February, the Lantern Festival, the 4th Fosun Family Season, which was held for 72 days, concluded successfully with the inaugural digital lighting ceremony of the 2024 Yuyuan Garden Lantern Festival. This year's Fosun Family Season was held during the Chinese New Year period for the first time. Centering around "Celebrating Chinese New Year with Fosun,” it